For clinical trial sponsors, some highlights include:
– eIC is a process, all stages of which must comply with the FDA regulations;
– Electronic signatures must comply with 21 CFR Part 11, a complex regulation that poses logistical problems for many trial sites;
– HIPAA authorizations may also be signed electronically if they are valid under applicable laws and regulations, such as E-Sign (consider whether the eIC process also complies with HIPAA);
– For IDE submissions, sponsors must include copies of all forms and materials provided to subjects as part of informed consent, and this will now include the eIC materials; and
– Subject identity authentication/nonrepudiation, data integrity, privacy and security are paramount for the eIC process.
While eIC should make the consent process more efficient, making sure the research institutions have appropriate measures in place to meet FDA requirements (including this draft guidance and Part 11) and industry standards will be a challenge. Sponsors will want to work with investigators and the institutions, including IRBs that have oversight responsibility for informed consent, to ensure the requirements are met.
The contents of this post should not be construed as legal advice or a legal opinion on any specific facts or circumstances. This content is not intended to and does not, by its receipt, create an attorney-client relationship. The contents are intended for general informational purposes only. We urge you to consult your attorney about the specific situation and any legal questions you may have. Attorney advertising in some jurisdictions. © 2023 Leibowitz Law. All rights reserved. “Leibowitz Law” is a trade name of Leibowitz LLC.
To be notified when we post new Insights, please sign up for our email list. As industry thought leaders, Leibowitz Law Insights address developing issues at the intersection of law, regulation, technology and life sciences.